NCT03585556 - AAVCAGsCD59 for the Treatment of Wet AMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2018

Primary Completion Date

January 29, 2020

Study Completion Date

January 18, 2022

Conditions

Wet Age-related Macular Degeneration

Interventions

DRUG

Intravitreal anti-VEGF

Intravitreal injection of anti-VEGF at Day 0 then monthly as needed

BIOLOGICAL

Intravitreal AAVCAGsCD59

An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once

DRUG

Oral prednisolone

A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients

Trial Locations (2)

Ophthalmic Consultants of Boston, Boston

Vitreo-Retina Associates, Worcester

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY